Company Profile

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Aurangabad manufacturing facility. The inspection was conducted from March 6 to March 15, 2024. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin is currently trading at Rs. 1595.15, up by 14.60 points or 0.92% from its previous closing of Rs. 1580.55 on the BSE. 

The scrip opened at Rs. 1595.00 and has touched a high and low of Rs. 1602.50 and Rs. 1588.15 respectively. So far 7418 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1703.80 on 11-Mar-2024 and a 52 week low of Rs. 680.35 on 27-Apr-2023.

Last one week high and low of the scrip stood at Rs. 1634.00 and Rs. 1541.05 respectively. The current market cap of the company is Rs. 72646.57 crore.

The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 46.05% and 6.93% respectively.

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Aurangabad manufacturing facility. The inspection was conducted from March 6 to March 15, 2024. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin has launched Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (USFDA).

Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc. Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of $1,019 million in the U.S. (IQVIA MAT February 2024).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Pursuant to Regulation 29(1)(a) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Lupin has informed that a meeting of the Board of Directors of the Company will be held on Monday, May 6, 2024, to consider and take on record audited financial results of the Company for the quarter and year-ended March 31, 2024 and recommend dividend, if any.

The above information is a part of company’s filings submitted to BSE.

Lupin is currently trading at Rs. 1594.85, up by 47.80 points or 3.09% from its previous closing of Rs. 1547.05 on the BSE.

The scrip opened at Rs. 1599.50 and has touched a high and low of Rs. 1603.00 and Rs. 1570.35 respectively. So far 14575 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1703.80 on 11-Mar-2024 and a 52 week low of Rs. 678.90 on 20-Apr-2023.

Last one week high and low of the scrip stood at Rs. 1640.00 and Rs. 1541.05 respectively. The current market cap of the company is Rs. 72851.65 crore.

The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 46.05% and 6.93% respectively.

Lupin has launched Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (USFDA).
Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc. Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of $1,019 million in the U.S. (IQVIA MAT February 2024).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.